Cancer Biopsy Market Size, Share Report, Analysis, Trends, Growth, Forecast, 2024 - 2032

Cancer Biopsy Market

Cancer Biopsy Market - By Product (Kits & Consumables and Instruments), By Type (Tissue Biopsies and Liquid Biopsies), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032

Category: Healthcare Report Format : PDF Pages: 150 Report Code: ZMR-6534 Published Date: Nov-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 5.22 Billion USD 79.78 Billion 35.4% 2023

Cancer Biopsy Market Insights

According to a report from Zion Market Research, the global Cancer Biopsy Market was valued at USD 5.22 Billion in 2023 and is projected to hit USD 79.78 Billion by 2032, with a compound annual growth rate (CAGR) of 35.4% during the forecast period 2024-2032. This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Cancer Biopsy Market industry over the next decade.

Cancer Biopsy Market SizeRequest Free Sample

Global Cancer Biopsy Market Size Analysis

The report offers assessment and analysis of the cancer biopsy market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion).

Cancer Biopsy Market: Overview

A biopsy is the most commonly utilized clinical tests in which tissue samples are gathered and examined for determining whether the lump of cell tissues are hazardous or not. In cancer biopsy, physician removes small sample of tissues from easily accessible parts of human body or internal body parts and sends it to lab for examining them under microscope. Furthermore, tissue samples are also removed in outpatient settings for determining whether the tissues are cancer cells or not. In addition to this, common cancer biopsies include cervical, breast, skin, and prostate gland biopsies. In addition to this, sample of tissues can be derived from stomach, liver, muscles, and thyroid.

Moreover, when physician feels something unusual at time of physical examining of patient, the doctor can perform biopsy. Apparently, biopsies can be necessary for clarifying whether imaging methods like x-rays & ultrasound techniques demonstrate abnormal tissue areas.

Global Cancer Biopsy MarketRequest Free Sample

Cancer Biopsy Market: Growth Drivers

Massive application of liquid biopsy and breakthroughs in biopsy methods are slated to steer expansion of cancer biopsy market over forthcoming years. In addition to this, minimal invasive nature of deriving circulating tumor cells has made biopsy as most popular tool in detecting various kinds of cancer in patients. Apparently, introduction of new techniques such as next-generation sequencing will embellish industry space in upcoming years. Furthermore, a prominent role played by image-driven needle biopsies in domain of precision medicine will proliferate size of cancer biopsy market over ensuing years.

Moreover, surging molecular assays is key to expansion of cancer biopsy industry. Additionally, in clinical studies, biopsies are also utilized for identifying drug response rate for patients receiving epidermal growth factor receptor treatments. This will further drive market trends. Apart from this, increase in number of medical trials in biomarker research activities will expand cancer biopsy market size.

Cancer Biopsy Market: Report Scope

Report Attributes Report Details
Report Name Cancer Biopsy Market
Market Size in 2023 USD 5.22 Billion
Market Forecast in 2032 USD 79.78 Billion
Growth Rate CAGR of 35.4%
Number of Pages 150
Key Companies Covered Qiagen N.V., Hologic, Inc., Illumina, Inc., Biocept, Inc., ANGLE Plc, Danaher Corporation, Roche Holding AG, GRAIL, Inc., Freenome Holdings, Inc., Lucence Diagnostics Private Limited, Epigenomics AG, HelioHealth, Genesystems, Inc., Natera, Inc., Chronix Biomedical , Inc., Personal Genome Diagnostics Inc., Personalis Inc., and Biodesix.
Segments Covered By Type, By Product, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2023
Historical Year 2018 to 2022
Forecast Year 2024 - 2032
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Cancer Biopsy Market: Regional Landscape

North America To Make Notable Contributions Towards Overall Market Size By 2028

The expansion of cancer biopsy industry in North America during assessment period is owing to prominent surge in number of diagnostic kit manufacturers & distributors in the sub-continent. Rise in acceptance of liquid biopsies in the U.S. will create lucrative growth avenues for cancer biopsy industry in North America during assessment period.

Cancer Biopsy Market:  Competitive Landscape

Key players profiled in report and leveraging market growth are 

  • Qiagen N.V.
  • Hologic.Inc.
  • Illumina.Inc.
  • Biocept.Inc.
  • ANGLE Plc
  • Danaher Corporation
  • Roche Holding AG
  • GRAIL.Inc.
  • Freenome Holdings.Inc.
  • Lucence Diagnostics Private Limited
  • Epigenomics AG
  • HelioHealth
  • Genesystems.Inc.
  • Natera.Inc.
  • Chronix Biomedical.Inc.
  • Personal Genome Diagnostics Inc.
  • Personalis Inc.
  • Biodesix.

The global Cancer Biopsy Market is segmented as follows:

By Product

  • Kits & Consumables
  • Instruments

By Type

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Massive application of liquid biopsy and breakthroughs in biopsy methods are slated to steer expansion of cancer biopsy market over forthcoming years. In addition to this, minimal invasive nature of deriving circulating tumor cells has made biopsy as most popular tool in detecting various kinds of cancer in patients. Apparently, introduction of new techniques such as next-generation sequencing will embellish industry space in upcoming years. Furthermore, a prominent role played by image-driven needle biopsies in domain of precision medicine will proliferate size of cancer biopsy market over ensuing years.

Moreover, surging molecular assays is key to expansion of cancer biopsy industry. Additionally, in clinical studies, biopsies are also utilized for identifying drug response rate for patients receiving epidermal growth factor receptor treatments. This will further drive market trends. Apart from this, increase in number of medical trials in biomarker research activities will expand cancer biopsy market size. 

According to Zion market research report, the global cancer biopsy market accrued earnings worth approximately USD 5.22 Billion in 2023 and projected to USD 79.78 Billion by 2032, with a CAGR of around 35.4% between 2024-2032.

 

 

North America will contribute lucratively towards the global market size over the estimated timeline. The regional market surge is due to prominent surge in number of diagnostic kit manufacturers & distributors in the sub-continent. Rise in acceptance of liquid biopsies in the U.S. will create lucrative growth avenues for cancer biopsy industry in North America during assessment period.    

The key market participants include Qiagen N.V., Hologic, Inc., Illumina, Inc., Biocept, Inc., ANGLE Plc, Danaher Corporation, Roche Holding AG, GRAIL, Inc., Freenome Holdings, Inc., Lucence Diagnostics Private Limited, Epigenomics AG, HelioHealth, Genesystems, Inc., Natera, Inc., Chronix Biomedical , Inc., Personal Genome Diagnostics Inc., Personalis Inc., and Biodesix.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed